D-0133-2025 Class II Ongoing
FDA drug recall D-0133-2025 was initiated by Mylan Institutional, Inc. on Nov 19, 2024 and is designated Class II. Reason for recall: Subpotent and Superpotent Drug The recall status is ongoing. Affected quantity: 1,664 cartons.
Recall Details
- Product Type
- Drugs
- Report Date
- Dec 18, 2024
- Initiation Date
- Nov 19, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1,664 cartons
Product Description
Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-443-20
Reason for Recall
Subpotent and Superpotent Drug
Distribution Pattern
Nationwide in the USA.
Code Information
Lot #: 3115893, Exp. Date 6/2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0133-2025
- openFDA file date
- Nov 3, 2026
- Loaded by RegDataLab
- Nov 4, 2026